Wanyi Hu

1.3k total citations
19 papers, 439 citations indexed

About

Wanyi Hu is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Wanyi Hu has authored 19 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 12 papers in Oncology and 7 papers in Hematology. Recurrent topics in Wanyi Hu's work include Protein Degradation and Inhibitors (13 papers), Peptidase Inhibition and Analysis (9 papers) and Ubiquitin and proteasome pathways (7 papers). Wanyi Hu is often cited by papers focused on Protein Degradation and Inhibitors (13 papers), Peptidase Inhibition and Analysis (9 papers) and Ubiquitin and proteasome pathways (7 papers). Wanyi Hu collaborates with scholars based in United States, China and Poland. Wanyi Hu's co-authors include Guangrong Zheng, Daohong Zhou, Yaxia Yuan, Xingui Liu, Xuan Zhang, Peiyi Zhang, Nathan J. Schauer, Xiaoxi Liu, Sara J. Buhrlage and Sajid Khan and has published in prestigious journals such as Nature Communications, Blood and Cancer Research.

In The Last Decade

Wanyi Hu

18 papers receiving 437 citations

Peers

Wanyi Hu

ONCOL

HEMAT

EPIDE

Stacey-Lynn Paiva United States

Oscar W. Huang United States

Anne Mirabella United States

Jasper E. Neggers United States

Irene Riz United States

Sarah Vittori United States

Catherine Berset Switzerland

Jenny Vu United States

Markus Schick Germany

Juran Kato‐Stankiewicz United States

Stacey-Lynn Paiva United States

Wanyi Hu

499 ×1.3

213 ×1.2

ONCOL

88 ×1.2

HEMAT

34 ×0.8

EPIDE

29 ×1.1

Citations per year, relative to Wanyi Hu Wanyi Hu (= 1×) peers Stacey-Lynn Paiva

Countries citing papers authored by Wanyi Hu

Since Specialization

Citations

This map shows the geographic impact of Wanyi Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wanyi Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wanyi Hu more than expected).

Fields of papers citing papers by Wanyi Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wanyi Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wanyi Hu. The network helps show where Wanyi Hu may publish in the future.

Co-authorship network of co-authors of Wanyi Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Wanyi Hu. A scholar is included among the top collaborators of Wanyi Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wanyi Hu. Wanyi Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

He, Yonghan, Chunbao Sun, Peiyi Zhang, et al.. (2025). A BCL-xL/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice. Nature Aging. 5(3). 386–400. 10 indexed citations

Zhang, Xuan, Dinesh Thummuri, Wanyi Hu, et al.. (2025). Discovery of XZ338, a highly potent BCL-XL degrader. European Journal of Medicinal Chemistry. 291. 117624–117624. 1 indexed citations

Zhang, Peiyi, Dinesh Thummuri, Wanyi Hu, et al.. (2025). Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader. RSC Medicinal Chemistry. 16(8). 3495–3506.

Poddar, Saikat Kumar, Yang Yang, Jin Zeng, et al.. (2025). Discovery of Dual BCL-xL/BCL-w Degraders by Exploiting the Bis(sulfonyl)benzene Ring of ABT-263 as a Linkage Vector. Journal of Medicinal Chemistry. 68(17). 18684–18702. 1 indexed citations

Bricelj, Aleša, Yuen Lam Dora Ng, Martina Gobec, et al.. (2024). Design, Synthesis, and Evaluation of BCL‐2 Targeting PROTACs. Chemistry - A European Journal. 30(45). e202400430–e202400430. 3 indexed citations

Nayak, Digant, Dongwen Lv, Yaxia Yuan, et al.. (2024). Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nature Communications. 15(1). 2743–2743. 23 indexed citations

Li, Hongna, Shamsur Rehman, Liang Qiao, et al.. (2024). Chromosome-scale assembly and annotation of the wild wheat relative Aegilops comosa. Scientific Data. 11(1). 1454–1454. 6 indexed citations

Chen, Hui, et al.. (2024). Targeted degradation of specific TEAD paralogs by small molecule degraders. Heliyon. 10(18). e37829–e37829. 3 indexed citations

Mitchell, Andrew D., Jing Wang, Chaomei Liu, et al.. (2024). Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL. Blood. 144(Supplement 1). 2786–2786. 1 indexed citations

10.

Yang, Yang, Wanyi Hu, Peiyi Zhang, et al.. (2023). Abstract B009: A liver-tropic BCL-xL PROTAC effectively clears senescent hepatocytes and prevents NASH-driven HCC in mice. Cancer Research. 83(2_Supplement_1). B009–B009. 1 indexed citations

11.

Pei, Jing, Yufeng Xiao, Xingui Liu, et al.. (2023). Piperlongumine conjugates induce targeted protein degradation. Cell chemical biology. 30(2). 203–213.e17. 48 indexed citations

12.

Liu, Xiaoxi, Robert S. Magin, Scott B. Ficarro, et al.. (2023). Accelerating inhibitor discovery for deubiquitinating enzymes. Nature Communications. 14(1). 686–686. 46 indexed citations

13.

Wang, Jian, Hongyu Li, Shamsur Rehman, et al.. (2023). High-resolution genetic mapping and identification of candidate genes for the wheat stem rust resistance gene Sr8155B1. The Crop Journal. 11(6). 1852–1861. 2 indexed citations

14.

Liu, Chaomei, Wanyi Hu, Peiyi Zhang, et al.. (2022). Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader. Blood. 140(Supplement 1). 497–498. 4 indexed citations

15.

Khan, Sajid, J Wiegand, Peiyi Zhang, et al.. (2022). Abstract 5313: A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers. Cancer Research. 82(12_Supplement). 5313–5313. 1 indexed citations

16.

Thummuri, Dinesh, Dongwen Lv, Xingui Liu, et al.. (2021). Discovery of a Novel BCL-X_L PROTAC Degrader with Enhanced BCL-2 Inhibition. Journal of Medicinal Chemistry. 64(19). 14230–14246. 42 indexed citations

17.

Bushman, Jonathan W., Katherine A. Donovan, Nathan J. Schauer, et al.. (2020). Proteomics-Based Identification of DUB Substrates Using Selective Inhibitors. Cell chemical biology. 28(1). 78–87.e3. 26 indexed citations

18.

Zhang, Xuan, Dinesh Thummuri, Xingui Liu, et al.. (2020). Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. European Journal of Medicinal Chemistry. 192. 112186–112186. 84 indexed citations

19.

Lamberto, Ilaria, Xiaoxi Liu, Hyuk‐Soo Seo, et al.. (2017). Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. Cell chemical biology. 24(12). 1490–1500.e11. 137 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact